Clean Tech Leader Aymium Defeats Stora Enso at European Patent Office Boards of Appeal
Cleantech leader Aymium defeated a challenge by Stora Enso to one of Aymium's patents (European Patent EP2697185) that provides exclusive rights to produce, sell and use bio-based materials for ...
JD Supra1d
The UPC and EPO Divide: Understanding Conflicting Revocation Proceeding Outcomes
With nearly 800 cases adjudicated or pending thus far at the Unified Patent Court (UPC), a possible procedural gap has ...
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...
Reuters8d
European Patent Office declares CureVac mRNA patent valid
March 27 (Reuters) - The European Patent Office declared a patent owned by CureVac (5CV.DE), opens new tab, valid, after a challenge from drugmaker BioNTech (22UAy.DE), opens new tab, the company ...
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...
MacTech8d
Apple had the fifth most number of patent applications at the European Patent Office in 2024
Companies and inventors from around the world filed 199,264 patent applications at the European Patent Office (EPO) last year ...
Lawmakers seek clarity on patents withdrawal from EU Industry Commissioner
Lawmakers of the European Parliament’s Legal Affairs committee have demanded clarity from the European Commission on its ...
CureVac says European Patent Office dismissed BioNTech opposition
CureVac (CVAC) announced that the European Patent Office has confirmed the validity of the company’s European patent EP 3 708 668 B1 subject to ...
CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...
European innovation keeps pace despite economic uncertainty
The European Patent Office’s latest report shows patent filings holding steady, with computer technology leading growth.
European Patent Office declares CureVac mRNA patent valid
The European Patent Office declared a patent owned by CureVac valid, after a challenge from drugmaker BioNTech, the company said on Thursday. U.S.-listed shares of Germany-based CureVac rose 11.8% in ...
Nasdaq7d
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form Confirming validity of ...